Analysis: Capitol Hill drug pricing reform opponents among t

Democratic Party lawmakers holding up proposed drug pricing reforms are among the largest beneficiaries of the pharmaceutical industry's push to stave off price cuts, a Reuters analysis of public lobbying and campaign data shows.

Related Keywords

New York , United States , Arizona , California , New Jersey , Washington , White House , District Of Columbia , Americans , Ahmed Aboulenein , Lovisa Gustafsson , Carl Odonnell , Scott Peters , Joe Biden , Frank Pallone , Kyrsten Sinema , Larry Levitt , Robert Menendez , America Ph , Caroline Humer , Amgen , Thomson Reuters Trust Principles , Commonwealth Fund , Members Of Congress , Democratic Party , Kaiser Family Foundation , Reuters , Pfizer , Pfizer Inc , Reform Committee , Amgen Inc , Pharmaceutical Research , Senators Kyrsten Sinema , Representative Scott Peters , Lower Drug Costs Now Act , Executive Steve Ubl , House Oversight , Carlo Donnell , Thomson Reuters Trust , Us , Health , Susa , Drugpricing , Lobbying , Analysis , Advocacy Groups Pressure Lobbies , Analyses , Company News , Enterprise Reporting , Healthcare Policy , Health Medicine , Us House Of Representatives , Insurance Trbc Level 3 , Workforce , Pictures , Major News , Pharmaceuticals Nec Trbc Level 5 , Pharmaceuticals Amp Medical Research Trbc Level 2 , Corporate Market Regulation , Us Senate , Us Government News ,